According to Lyra Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.3843. At the end of 2023 the company had a P/S ratio of 177.
Year | P/S ratio | Change |
---|---|---|
2023 | 177 | 141.11% |
2022 | 73.3 | -63.15% |
2021 | 199 | |
2020 | N/A |